Mitemcinal

Star0

DB06587InvestigationalSmall molecule

Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

Mechanism: Mitemcinal, an oral motilin agonist, accelerates gastric emptying.
Curator reviewed
Primary indication: Investigated for use/treatment in gastroparesis and irritable bowel syndrome (IBS).Curator reviewed
Formula / weight: C₄₀H₆₉NO₁₂ · 755.987 g/mol (avg)

Resolves to

Compound

UNII6X5NRJ664LCAS154738-42-8ChEMBLCHEMBL2110756

Structure

InChIKeyBELMMAAWNYFCGF-PZXAHSFZSA-NSMILES

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C(C)C)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC

Targets

O43193MLNR

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

317Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mitemcinal, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account